Home > Journals > Minerva Urologica e Nefrologica > Past Issues > Minerva Urologica e Nefrologica 2001 September;53(3) > Minerva Urologica e Nefrologica 2001 September;53(3):159-70

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Reprints
Permissions

 

REVIEWS   

Minerva Urologica e Nefrologica 2001 September;53(3):159-70

Copyright © 2001 EDIZIONI MINERVA MEDICA

language: English

Therapy of hyperhomocysteinemia in end-stage renal disease patients

Hagen W., Födinger M., Hörl W. H., Sunder-Plassmann G.

From the Division of Nephrology and Dialysis Department of Medicine III *Division of Endocrinology Department of Laboratory Medicine University of Vienna, Vienna, Austria


PDF


Because of a potential association with cardiovascular disease, birth defects, and various other conditions, an elevation of tHcy plasma levels has gained broad interest. The majority of chronic renal failure patients present with hyperhomocysteinemia, the causes of which are not completely understood. An increasing number of studies addressed the treatment of hyperhomocysteinemia in chronic renal failure patients. Folic acid combined with vitamin B6 and vitamin B12 is more effective in lowering tHcy levels than either cofactor alone. The optimal dose of folic acid appears to be 1 mg orally per day. Intravenous application of vitamin B12, giving 1 to 1.5 mg per week may be more effective than therapy with 1 mg orally per day. The role of vitamin B6 is far from clear. It may play a role in combination with folic acid and/or vitamin B12. Finally, general screening for and treatment of hyperhomocysteinemia is not recommended.

top of page